预约演示

Accent Therapeutics secures funding to advance cancer therapies

2024-01-24

临床1期

The Series C financing will support the advancement of innovative oncology drug candidates through early clinical trials. Credit: Aunt Spray/Shutterstock.com.

Accent Therapeutics has announced the successful completion of a $75m Series C financing round to progress the development of small molecule precision cancer therapies.

Accent Therapeuticsheaded by Mirae Asset Capital Life Science and saw contributions from new investors including Mirae Asset Capital, Mirae Asset Ventucancerestment, Bristol Myers Squibb and Johnson & Johnson Innovation.

Current investors AbbVie Ventures, Atlas Venture, the Column Group, Droia Ventures, EcoR1 Capital, GV, the Mark FMirae Asset Capitalr Research and Timefolio Capital wBristol Myers SquibbticipJohnson & Johnson Innovation

The funds will be AbbVie VenturesclAtlas Venturepment of Accent’s leading drug candidates.Mark Foundation for Cancer Research Cancer Timefolio Capital

These include a DExH-Box Helicase 9 (DHX9) inhibitor and a kinesin family member 18A (KIF18A) inhibitor, with a focus on safety, pharmacokinetics and early efficacy studies.

Mirae Asset CapiDExH-Box Helicase 9 (DHX9)director Naveen Kkinesin family member 18A (KIF18A) inhibitor kinesin family member 18A (KIF18A)’s board of directors.

Accent’s lead candidate, a DHX9 inhibitor, is aimed at treating cancers with significanAccentt medical needs, such as those associated with breast cancer gene (BRCA) loss of function (breast and ovarian cancers) and mismatch repair deficiency (colorectal, endometrial and gastric cancers).

The company’s second lead pDHX9amme, a KIF18A inhibitor, has thecancersial to address a wide range of cancer indications with high unmet needs, including triple-negative breast cancer breast and ovarian cancers

Accent Therapeutics CEO Shakti Narayan KIF18A inhibitor KIF18A: “We are delighted to announce the backing of an excepticancernvestor syndicate [that shares] our commitmenttriple-negative breast cancerapiesovarian cancerwith cancer.

Accent Therapeuticsesources position us well to file INDs [investigational new drug applications] this year for both our DHX9 and KIF18A programmes, and to rapidly progress them through early clinical develocancer”

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构